Some patients with advanced colorectal cancer that once carried a grim prognosis are now alive three years after starting a ...

Patients with metastatic colorectal cancer that had stopped responding to at least two prior treatment regimens gained meaningful extra months of life when bevacizumab was added to the chemotherapy ...

Analysis of 35,213 patients with stage II-III colon cancer revealed that recurrence risk drops below 0.5% at 6 years post-surgery, supporting a practical definition of cure. Women showed a ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Researchers have unveiled a breakthrough showing that a subset of ...

Defining cure in stage II and III colon cancer has been challenging, and has never been systematically studied. In an analysis of 15 randomized trials, colon cancer relapse risk fell to 0.5% by year 6 ...

Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...

Molecular profiling (e.g., MSI, RAS, BRAF) is essential to align patients with targeted therapies and immunotherapy, and should be obtained early to avoid missed actionable options. Precision oncology ...

Researchers identified a six-gene signature in microscopic colorectal cancer (CRC) liver metastases that may help predict ...

Dr. Eng Breaks Down Braftovi Plus Erbitux FDA Approval in BRAF+ mCRC Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types.

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for ...